Novo Nordisk has begun manufacturing and packaging operations for its newly approved Wegovy weight-loss pill at its facilities in North Carolina, following clearance from the U.S. Food and Drug Administration. The product marks the first GLP-1 weight-loss medication available in pill form in the United States.
Video footage released by the company offers a rare look at the packaging line in operation, showing the process from pill presentation through to robotic case packing. The line combines mechanical handling systems with robotics, including rotary operations and timing screws, to manage the flow of square plastic bottles through the system.
The decision to use a square bottle format stands out in pharmaceutical packaging, where round bottles are typically preferred for higher line speeds. Novo Nordisk has not disclosed specific throughput figures for the line, but the footage suggests the company is relying on a hybrid of automation technologies to support the anticipated demand. While square bottles can be more challenging to handle at high speeds, the format offers advantages in terms of shelf differentiation and cube efficiency during transport.
Novo Nordisk declined to provide guidance on expected production volumes for the Wegovy pill in 2026. However, Liz Skrbkova, senior director for Media & Stakeholder Relations at the company, pointed to strong early interest following the launch.
“Since launch, we have seen patients from all over the country ask for the Wegovy pill. It’s early days but what’s clear is people have been waiting for Wegovy pill. There’s only one and it’s made by Novo Nordisk, end-to-end, right here in the US,” she said.
According to the company, all dose strengths of the Wegovy pill are now available nationwide in the US. Distribution spans more than 70,000 pharmacies, including major retail chains such as CVS and Costco, as well as Novo Nordisk’s own NovoCare Pharmacy. The product is also accessible via selected telehealth providers and digital health platforms.
Skrbkova added that the company is monitoring the market response closely but cautioned against drawing early conclusions. “Early signs are positive, and we are encouraged by feedback from our collaborators,” she said. “It’s too early for us to speak about trends for Wegovy pill but we’ll continue all our efforts to reach as many Americans as possible.”
The launch of an oral GLP-1 therapy, combined with a purpose-designed packaging line, underlines the growing role of packaging strategy in supporting pharmaceutical innovation, scale-up and market differentiation.
